Rpo LLC Makes New $50,000 Investment in Alector, Inc. (NASDAQ:ALEC)

Rpo LLC bought a new stake in Alector, Inc. (NASDAQ:ALEC) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 26,395 shares of the company’s stock, valued at approximately $50,000.

Other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of Alector by 64.7% during the third quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock worth $12,716,000 after purchasing an additional 1,072,298 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Alector by 18.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,017,687 shares of the company’s stock worth $4,742,000 after purchasing an additional 159,111 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Alector by 8.5% during the third quarter. Geode Capital Management LLC now owns 1,903,942 shares of the company’s stock worth $8,874,000 after purchasing an additional 148,357 shares in the last quarter. FMR LLC grew its holdings in Alector by 1.0% during the 3rd quarter. FMR LLC now owns 14,595,014 shares of the company’s stock valued at $68,013,000 after purchasing an additional 137,794 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Alector during the 3rd quarter valued at $639,000. 85.83% of the stock is owned by hedge funds and other institutional investors.

Alector Stock Up 1.7 %

Shares of Alector stock opened at $1.18 on Thursday. The business has a 50-day moving average price of $1.56 and a 200 day moving average price of $2.88. Alector, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $6.78. The firm has a market cap of $116.92 million, a P/E ratio of -0.69 and a beta of 0.65.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The business had revenue of $54.24 million during the quarter, compared to the consensus estimate of $20.41 million. As a group, equities research analysts anticipate that Alector, Inc. will post -1.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Alector in a research report on Thursday, February 27th. Stifel Nicolaus cut Alector from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research note on Monday, December 16th. Morgan Stanley restated an “underweight” rating and set a $1.50 price objective (down previously from $3.00) on shares of Alector in a research note on Friday, March 7th. Bank of America lowered Alector from a “neutral” rating to an “underperform” rating and cut their target price for the company from $9.00 to $1.00 in a research report on Wednesday, December 4th. Finally, Mizuho downgraded shares of Alector from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $9.00 to $2.50 in a research report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.50.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.